Cell‐Based Therapies: The Nonresponder

Cell‐based therapies have come of age and several phase III trials are now being conducted. Cell‐based therapies, especially involving mesenchymal stem cells (MSCs), have substantial nonresponder rates, as has been reported in some current clinical trials. This high rate is expected as the MSCs are...

Descripción completa

Detalles Bibliográficos
Autor principal: Caplan, Arnold I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2018
Materias:
Perspectives
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6216418/
https://www.ncbi.nlm.nih.gov/pubmed/30251411
http://dx.doi.org/10.1002/sctm.18-0074
_version_ 1783368289714438144
author Caplan, Arnold I.
author_facet Caplan, Arnold I.
author_sort Caplan, Arnold I.
collection PubMed
description Cell‐based therapies have come of age and several phase III trials are now being conducted. Cell‐based therapies, especially involving mesenchymal stem cells (MSCs), have substantial nonresponder rates, as has been reported in some current clinical trials. This high rate is expected as the MSCs are neither tuned for each of the diseases that are being treated nor for the huge variance in the genetics and response characteristics of the individual patients being treated. Such nonresponders might be used as a control group, thus eliminating the need for placebo controls. stem cells translational medicine 2018;7:762–766
format Online
Article
Text
id pubmed-6216418
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-62164182018-11-08 Cell‐Based Therapies: The Nonresponder Caplan, Arnold I. Stem Cells Transl Med Perspectives Cell‐based therapies have come of age and several phase III trials are now being conducted. Cell‐based therapies, especially involving mesenchymal stem cells (MSCs), have substantial nonresponder rates, as has been reported in some current clinical trials. This high rate is expected as the MSCs are neither tuned for each of the diseases that are being treated nor for the huge variance in the genetics and response characteristics of the individual patients being treated. Such nonresponders might be used as a control group, thus eliminating the need for placebo controls. stem cells translational medicine 2018;7:762–766 John Wiley & Sons, Inc. 2018-09-25 /pmc/articles/PMC6216418/ /pubmed/30251411 http://dx.doi.org/10.1002/sctm.18-0074 Text en © 2018 The Authors. stem cells translational medicine published by Wiley Periodicals, Inc. on behalf of AlphaMed Press This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Perspectives
Caplan, Arnold I.
Cell‐Based Therapies: The Nonresponder
title Cell‐Based Therapies: The Nonresponder
title_full Cell‐Based Therapies: The Nonresponder
title_fullStr Cell‐Based Therapies: The Nonresponder
title_full_unstemmed Cell‐Based Therapies: The Nonresponder
title_short Cell‐Based Therapies: The Nonresponder
title_sort cell‐based therapies: the nonresponder
topic Perspectives
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6216418/
https://www.ncbi.nlm.nih.gov/pubmed/30251411
http://dx.doi.org/10.1002/sctm.18-0074
work_keys_str_mv AT caplanarnoldi cellbasedtherapiesthenonresponder

Ejemplares similares